Ambrisentan for Treatment of Portopulmonary Hypertension
NCT01733095
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
WITHDRAWN
Status
OTHER
Sponsor class
Stopped
slow recruitment
Conditions
Portopulmonary Hypertension
Interventions
DRUG:
ambrisentan
Sponsor
Medical University of Graz